Compare SBH & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBH | NKTR |
|---|---|---|
| Founded | 1964 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2006 | 1996 |
| Metric | SBH | NKTR |
|---|---|---|
| Price | $18.77 | $36.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $22.00 | ★ $131.92 |
| AVG Volume (30 Days) | ★ 1.4M | 567.3K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.88 | N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $3,734,567,000.00 | $307,711,000.00 |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $1.62 | $40.13 |
| P/E Ratio | $9.38 | ★ N/A |
| Revenue Growth | 0.90 | ★ 86.00 |
| 52 Week Low | $11.54 | $33.40 |
| 52 Week High | $21.06 | $109.00 |
| Indicator | SBH | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 36.25 |
| Support Level | $15.09 | $35.68 |
| Resistance Level | N/A | $40.12 |
| Average True Range (ATR) | 0.92 | 1.65 |
| MACD | -0.01 | 0.75 |
| Stochastic Oscillator | 40.97 | 15.98 |
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. The company operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, Netherlands, and other geographical regions. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. The products offered by the company include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.